PKMYT1 is associated with prostate cancer malignancy and may serve as a therapeutic target

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Prostate cancer (PCa) is a global health concern, necessitating new therapeutic strategies.
• Identifying novel molecular targets is crucial for improving PCa treatment outcomes.

Purpose of the Study:

• To discover novel therapeutic targets for PCa using advanced analysis of The Cancer Genome Atlas (TCGA) RNA sequencing data.
• To identify genes associated with PCa malignancy and potential therapeutic intervention points.

Main Methods:

• Weighted gene co-expression network analysis (WGCNA) on PCa RNAseq data to identify relevant gene modules.
• Differential gene expression and survival analyses to pinpoint potential therapeutic targets.
• In vitro functional assays (proliferation, cell cycle, colony formation) to validate target gene function.

Main Results:

• PKMYT1 was identified as a key gene module associated with PCa Gleason score.
• Knockdown of PKMYT1 significantly inhibited PCa cell proliferation and growth.
• PKMYT1 promotes PCa growth by regulating CCNB1 and CCNE1 expression.
• Fostamatinib, a PKMYT1 inhibitor, demonstrated anti-proliferative effects on PCa cells.

Conclusions:

• PKMYT1 plays a significant role in prostate cancer progression and malignancy.
• PKMYT1 represents a promising novel therapeutic target for prostate cancer treatment.
• Targeting PKMYT1, potentially with inhibitors like fostamatinib, could offer a new therapeutic avenue for PCa.